natgillin/translations-raw huggingface dataset:
1000 International Units/vial simoctocog alfa (400 IU/ml after reconstitution)
1000 mednarodnih enot/vialo simoktokog alfa (400 i.e./ml po rekonstituciji)
1000 IU (100 IU/ml after reconstitution)
1000 i.e. (100 i.e./ml po pripravi).
1000 IU (octocog alfa) (400 IU/mL after reconstitution).
1000 a.e. (októkóg alfa) (400 a.e./ml eftir blöndun).
1000 IU human coagulation factor IX (100 IU/ml after reconstitution).
1000 i.e. humanega koagulacijskega faktorja IX (100 i.e./ml po pripravi).
1000 IU moroctocog alfa for single IV use
1.000 i.e. moroktokoga alfa za enkratno i.v. uporabo
1000 IU octocog alfa
1000 i.e. oktokoga alfa
1000 IU octocog alfa (400 IU/ml after reconstitution).
1000 i.e. oktokoga alfa (po rekonstituciji 400 i.e./ml).
1000 IU* human coagulation factor VIII** (FVIII)
1000 i.e.* humanega koagulacijskega faktorja VIII** (FVIII).
1000 IU/0.3ml
1000 i.e./0,3 ml
1000 IU/0.5 ml
1000 i.e. /
1000 IU/0.5 ml
1000 i.e./0,5 ml
1000 IU/mL after reconstitution)
1000 i.e./ml po rekonstituciji)
1000 IU/vial
1000 i.e./vialo
1000 mg BID
dvakrat na dan)
1000 mg q8h was given with efavirenz
1.000 mg q8h z efavirenzem
1000 mg sachets
1000- mg vrečice
1000 mg/day
1.000 mg/dan
1000 mg/kg/day).
1.000 mg/kg/dan).
1000 mg/m2
1.000 mg/m2
1000 mg/m2 oral twice daily
1.000 mg/m2 peroralno dvakrat na dan
1000 mg: 10, 20, 30, 50, 60, 100 x 1, 100 film-coated tablets and multipacks containing 200 (2 packs of 100) film-coated tablets
1000 mg: 10, 20, 30, 50, 60, 100 x 1, 100 filmsko obloženih tablet in v večkratnem pakiranju po 200 (2 pakiranji po 100) filmsko obloženih tablet.
1000 mg: polyvinyl alcohol, titanium dioxide (E171), macrogol, talc
1.000 mg: polivinilalkohol, titanov dioksid (E171), makrogol, smukec
1000 New Horizons Way Vacaville, CA 95688-9431 USA
1000 New Horizons Way Vacaville, CA 95688-9431 ZDA
1000 pigs with an average body weight of 50 kg).
1000 prašičev s povprečno telesno težo 50 kg).
1000 tablets (20 x 50 tablets)
1000 (20 x 50) tablet
1000 tablets (20 x 50 tablets)
1000 tablet (20 x 50 tablet)
1000 Units of Cinryze at the first sign of the onset of an angioedema attack.
1000 enot zdravila Cinryze pri prvem znaku začetka napada angioedema.
1000 Units of Cinryze every 3 or 4 days is the recommended starting dose for routine prevention against angioedema attacks; the dosing interval may need to be adjusted according to individual response.
1000 enot zdravila Cinryze vsake 3 ali 4 dni je priporočeni začetni odmerek za preprečevanje napadov angioedema; presledek med odmerki po potrebi prilagodite individualnemu odzivu.
1000 Units of Cinryze within 24 hours before a medical, dental, or surgical procedure.
1000 enot zdravila Cinryze 24 ur pred internističnim, stomatološkim ali kirurškim posegom.
1000 – 10,000 copies/ml
1.000 – 10.000 kopij/ml
1000 – Less than 1500
1.000–manj kot 1.500
1000/100 mg bid)
odmerek
10000 doses
10.000 odmerkov
10000 doses
odmerkov
10000 IU/1.0 ml
10.000 i.e./1,0
10000 IU/1.0 ml
10.000 IE/1,0
10000 IU/1.0 ml
10000 i.e./1,0 ml
100IU/ml
EU/1/97/030/021
100ml (50 doses)
100 ml (50 odmerkov)
100ml (50 doses)
100ml (50 odmerkov)
100x1 film-coated tablets
100x1 filmsko obložena tableta
100x1 film-coated tablets 28x1 film-coated tablets
28x1 filmsko obložena tableta
100x1 tablets (unit dose)
100 x 1 tableta (odmerek)
101 (40.6%)b
0,27
101 rue Saint Lazare 75009 Paris
101 rue Saint Lazare 75009 PARIZ
102 (30)
n=337
102 37 Prague 10 Czech Republic
102 37 Prague 10 Češka
102 37 Prague 10 Czech Republic
102 37 Prague 10 Češka republika
102 tablets
102 tableti
102 tablets (17 blister strips with 6 tablets each)
102 tableti (17 pretisnih omotov po 6 tablet)
10212 patients, 0.07%) HR=2.64 (95% CI 1.11-6.31, P=0.029).
10.212 bolnikov, 0,07 %) HR = 2,64 (95 % IZ 1,11-6,31, P = 0,029).
10212 patients, 0.07%) HR=2.64 (95% CI 1.11-6.31, P=0.029).
10.212 bolnikov, 0,07 %) HR = 2,64 (95% IZ 1,11-6,31, P = 0,029).
10212 patients, 0.07%) HR=2.64 (95% CI 1.11-6.31, P=0.029).
10.212 bolnikov, 0,07%) HR = 2,64 (95% IZ 1,11-6,31, P = 0,029).
103 (31)
n=331
103.8 micrograms/mL (Cmax) at 0.5 hour postdose (end of infusion), 13.5 micrograms/mL at 6 hour postdose, and 2.5 micrograms/mL at 12 hour postdose.
103,8 mikrogramov/ml (Cmax) 0,5 ure po odmerku (ob koncu infuzije), 13,5 mikrogramov/ml 6 ur po odmerku in 2,5 mikrograma/ml 12 ur po odmerku.
1030, Vienna, Austria.
1030, Vienna Avstrija
1030, Vienna, Austria.
1030, Vienna Avstrija.
104 weeks
26 tednov
104 weeks
78 tednov
104.3 TCID50 10 3.1 TCID50
103,6 TCID50
105 mg (1.05 ml) twice daily
105 mg (1,05 ml) dvakrat na dan
105 mg (1.05 ml) twice daily
105 mg (1.05 ml) dvakrat na dan
105 tablets
105 tablet
105.1 TCID50
105,3 TCID50
105.1 TCID50
106,6 TCID50
105.3 TCID50
Pasji parvovirus tipa 2b
106 (1 million) PFU/mL
106 (1 milijon) PFU/ml
106 (1 million) PFU/mL - For initial dose only.
106 (1 milijon) PFU/ml – samo za začetni odmerek.
106 (50.7%)a
320 (92%)a
106.,3- 108.3 CFU of live Bordetella bronchiseptica bacteria strain B-C2.
≥ 106,3- ≤ 108,3 CFU živih bakterij Bordetella bronchiseptica, sev B-C2
106.3- 108.3 CFU/dose B. bronchiseptica
106.,3- 108.,3 CFU/odmerek B. bronchiseptica
106.3-108.3 colony forming units (CFU) of live Bordetella bronchiseptica bacteria strain B-C2
≥ 106,3- ≤ 108,3 CFU živih bakterij Bordetella bronchiseptica, sev B-C2
106.3-108.3 colony forming units (CFU) of live Bordetella bronchiseptica strain B-C2
≥ 106,3- ≤ 108,3 CFU živih bakterij Bordetella bronchiseptica, sev B-C2
1060 patients were randomized to receive either docetaxel 75 mg/m2 administered 1-hour after doxorubicin 50 mg/m2 and cyclophosphamide 500 mg/m2 (539 patients in TAC arm), or doxorubicin 50 mg/m2 followed by fluorouracil 500 mg/m2 and cyclosphosphamide 500 mg/m2 (521 patients in FAC arm), as adjuvant treatment of operable node-negative breast cancer patients with high risk of relapse according to 1998 St. Gallen criteria (tumour size > 2 cm and/or negative ER and PR and/or high histological/nuclear grade (grade 2 to 3) and /or age < 35 years).
1060 bolnic je bilo naključno razporejenih na prejemanje zdravila Docetaksel 75 mg/m2 1 -uro po doksorubicinu 50 mg/m2 in ciklofosfamidu 500 mg/m2 (539 bolnic v kraku TAC), ali na prejemanje doksorubicina 50 mg/m2, ki sta mu sledila fluorouracil 500 mg/m2 in ciklofosfamid 500 mg/m2 (521 bolnic v kraku FAC) kot adjuvantnega zdravljenja operabilnega raka dojke z negativnimi bezgavkami pri bolnicah z velikim tveganjem recidiva po St.- Gallenskih merilih 1998 (velikost tumorja > 2 cm in/ali negativni ER in PR in/ali visoka histološka/jedrna stopnja (2. do 3. stopnja) in/ali starost < 35 let).
1060 patients were randomized to receive either docetaxel 75 mg/m2 administered 1-hour after doxorubicin 50 mg/m2 and cyclophosphamide 500 mg/m2 (539 patients in TAC arm), or doxorubicin 50 mg/m2 followed by fluorouracil 500 mg/m2 and cyclosphosphamide 500 mg/m2 (521 patients in FAC arm), as adjuvant treatment of operable node-negative breast cancer patients with high risk of relapse according to 1998 St. Gallen criteria (tumour size > 2 cm and/or negative ER and PR and/or high histological/nuclear grade (grade 2 to 3) and /or age < 35 years).
500 mg/m² (539 bolnic v kraku TAC), ali na prejemanje doksorubicina 50 mg/m², ki sta mu sledila fluorouracil 500 mg/m² in ciklofosfamid 500 mg/m² (521 bolnic v kraku FAC) kot adjuvantnega zdravljenja operabilnega raka dojke z negativnimi bezgavkami pri bolnicah z velikim tveganjem recidiva po St.-Gallenskih merilih 1998 (velikost tumorja > 2 cm in/ali negativni ER in PR in/ali visoka histološka/jedrna stopnja (2. do 3. stopnja) in/ali starost < 35 let).
1060 patients were randomized to receive either docetaxel 75 mg/m2 administered 1-hour after doxorubicin 50 mg/m2 and cyclophosphamide 500 mg/m2 (539 patients in TAC arm), or doxorubicin 50 mg/m2 followed by fluorouracil 500 mg/m2 and cyclosphosphamide 500 mg/m2 (521 patients in FAC arm), as adjuvant treatment of operable node-negative breast cancer patients with high risk of relapse according to 1998 St. Gallen criteria (tumour size > 2 cm and/or negative ER and PR and/or high histological/nuclear grade (grade 2 to 3) and /or age < 35 years).
Po stratifikaciji glede na število pozitivnih bezgavk (1-3, 4 ali več) je bilo 1.491 bolnic randomiziranih na prejemanje docetaksela 75 mg/m2, apliciranega 1 uro po doksorubicinu 50 mg/m2 in ciklofosfamidu 500 mg/m2 (krak TAC), ali na prejemanje doksorubicina 50 mg/m2, ki sta mu sledila fluorouracil 500 mg/m2 in ciklofosfamid 500 mg/m2 (krak FAC).
1060 patients were randomized to receive either DOCETAXEL KABI 75 mg/m2 administered 1-hour after doxorubicin 50 mg/m2 and cyclophosphamide 500 mg/m2 (539 patients in TAC arm), or doxorubicin 50 mg/m2 followed by fluorouracil 500 mg/m2 and cyclosphosphamide 500 mg/m2 (521 patients in FAC arm), as adjuvant treatment of operable node-negative breast cancer patients with high risk of relapse according to 1998 St. Gallen criteria (tumour size > 2 cm and/or negative ER and PR and/or high histological/nuclear grade (grade 2 to 3) and /or age < 35 years).).
1060 bolnic je bilo naključno razporejenih na prejemanje zdravila DOCETAKSEL KABI 75 mg/m2 1-uro po doksorubicinu 50 mg/m2 in ciklofosfamidu 500 mg/m2 (539 bolnic v kraku TAC), ali na prejemanje doksorubicina 50 mg/m2, ki sta mu sledila fluorouracil 500 mg/m2 in ciklofosfamid 500 mg/m2 (521 bolnic v kraku FAC) kot adjuvantnega zdravljenja operabilnega raka dojke z negativnimi bezgavkami pri bolnicah z velikim tveganjem recidiva po St.- Gallenskih merilih 1998 (velikost tumorja > 2 cm in/ali negativni ER in PR in/ali visoka histološka/jedrna stopnja (2. do 3. stopnja) in/ali starost < 35 let).
1060 patients were randomized to receive either Docetaxel Winthrop 75 mg/m2 administered 1-hour after doxorubicin 50 mg/m2 and cyclophosphamide 500 mg/m2 (539 patients in TAC arm), or doxorubicin 50 mg/m2 followed by fluorouracil 500 mg/m2 and cyclosphosphamide 500 mg/m2 (521 patients in FAC arm), as adjuvant treatment of operable node-negative breast cancer patients with high risk of relapse according to 1998 St. Gallen criteria (tumour size >2 cm and/or negative ER and PR and/or high histological/nuclear grade (grade 2 to 3) and /or age <35 years).
1060 bolnic je bilo naključno razporejenih na prejemanje zdravila Docetaxel Winthrop 75 mg/m2 1 -uro po doksorubicinu 50 mg/m2 in ciklofosfamidu 500 mg/m2 (539 bolnic v kraku TAC), ali na prejemanje doksorubicina 50 mg/m2, ki sta mu sledila fluorouracil 500 mg/m2 in ciklofosfamid 500 mg/m2 (521 bolnic v kraku FAC) kot adjuvantnega zdravljenja operabilnega raka dojke z negativnimi bezgavkami pri bolnicah z velikim tveganjem recidiva po St.-Gallenskih merilih 1998 (velikost tumorja > 2 cm in/ali negativni ER in PR in/ali visoka histološka/jedrna stopnja (2. do 3. stopnja) in/ali starost < 35 let).
1060 patients were randomized to receive either Docetaxel Winthrop 75 mg/m2 administered 1-hour after doxorubicin 50 mg/m2 and cyclophosphamide 500 mg/m2 (539 patients in TAC arm), or doxorubicin 50 mg/m2 followed by fluorouracil 500 mg/m2 and cyclosphosphamide 500 mg/m2 (521 patients in FAC arm), as adjuvant treatment of operable node-negative breast cancer patients with high risk of relapse according to 1998 St. Gallen criteria (tumour size >2 cm and/or negative ER and PR and/or high histological/nuclear grade (grade 2 to 3) and /or age <35 years).).
1060 bolnic je bilo naključno razporejenih na prejemanje zdravila Docetaxel Winthrop 75 mg/m2 1 -uro po doksorubicinu 50 mg/m2 in ciklofosfamidu 500 mg/m2 (539 bolnic v kraku TAC), ali na prejemanje doksorubicina 50 mg/m2, ki sta mu sledila fluorouracil 500 mg/m2 in ciklofosfamid 500 mg/m2 (521 bolnic v kraku FAC) kot adjuvantnega zdravljenja operabilnega raka dojke z negativnimi bezgavkami pri bolnicah z velikim tveganjem recidiva po St.-Gallenskih merilih 1998 (velikost tumorja > 2 cm in/ali negativni ER in PR in/ali visoka histološka/jedrna stopnja (2. do 3. stopnja) in/ali starost < 35 let).
1060 patients were randomized to receive either Taxespira 75 mg/m2 administered 1-hour after doxorubicin 50 mg/m2 and cyclophosphamide 500 mg/m2 (539 patients in TAC arm), or doxorubicin 50 mg/m2 followed by fluorouracil 500 mg/m2 and cyclosphosphamide 500 mg/m2 (521 patients in FAC arm), as adjuvant treatment of operable node-negative breast cancer patients with high risk of relapse according to 1998 St. Gallen criteria (tumour size >2 cm and/or negative ER and PR and/or high histological/nuclear grade (grade 2 to 3) and /or age <35 years).).
1060 bolnic je bilo naključno razporejenih na prejemanje zdravila Taxespira75 mg/m2 1 -uro po doksorubicinu 50 mg/m2 in ciklofosfamidu 500 mg/m2 (539 bolnic v kraku TAC), ali na prejemanje doksorubicina 50 mg/m2, ki sta mu sledila fluorouracil 500 mg/m2 in ciklofosfamid 500 mg/m2 (521 bolnic v kraku FAC) kot adjuvantnega zdravljenja operabilnega raka dojke z negativnimi bezgavkami pri bolnicah z velikim tveganjem recidiva po St.- Gallenskih merilih 1998 (velikost tumorja > 2 cm in/ali negativni ER in PR in/ali visoka histološka/jedrna stopnja (2. do 3. stopnja) in/ali starost < 35 let).
1060 patients were randomized to receive either TAXOTERE 75 mg/m2 administered 1-hour after doxorubicin 50 mg/m2 and cyclophosphamide 500 mg/m2 (539 patients in TAC arm), or doxorubicin 50 mg/m2 followed by fluorouracil 500 mg/m2 and cyclosphosphamide 500 mg/m2 (521 patients in FAC arm), as adjuvant treatment of operable node-negative breast cancer patients with high risk of relapse according to 1998 St. Gallen criteria (tumour size >2 cm and/or negative ER and PR and/or high histological/nuclear grade (grade 2 to 3) and /or age <35 years).
1060 bolnic je bilo naključno razporejenih na prejemanje zdravila TAXOTERE 75 mg/m2 1 -uro po doksorubicinu 50 mg/m2 in ciklofosfamidu 500 mg/m2 (539 bolnic v kraku TAC), ali na prejemanje doksorubicina 50 mg/m2, ki sta mu sledila fluorouracil 500 mg/m2 in ciklofosfamid 500 mg/m2 (521 bolnic v kraku FAC) kot adjuvantnega zdravljenja operabilnega raka dojke z negativnimi bezgavkami pri bolnicah z velikim tveganjem recidiva po St.- Gallenskih merilih 1998 (velikost tumorja > 2 cm in/ali negativni ER in PR in/ali visoka histološka/jedrna stopnja (2. do 3. stopnja) in/ali starost < 35 let).
1060 patients were randomized to receive either TAXOTERE 75 mg/m2 administered 1-hour after doxorubicin 50 mg/m2 and cyclophosphamide 500 mg/m2 (539 patients in TAC arm), or doxorubicin 50 mg/m2 followed by fluorouracil 500 mg/m2 and cyclosphosphamide 500 mg/m2 (521 patients in FAC arm), as adjuvant treatment of operable node-negative breast cancer patients with high risk of relapse according to 1998 St. Gallen criteria (tumour size >2 cm and/or negative ER and PR and/or high histological/nuclear grade (grade 2 to 3) and /or age <35 years).).
1060 bolnic je bilo naključno razporejenih na prejemanje zdravila TAXOTERE 75 mg/m2 1 -uro po doksorubicinu 50 mg/m2 in ciklofosfamidu 500 mg/m2 (539 bolnic v kraku TAC), ali na prejemanje doksorubicina 50 mg/m2, ki sta mu sledila fluorouracil 500 mg/m2 in ciklofosfamid 500 mg/m2 (521 bolnic v kraku FAC) kot adjuvantnega zdravljenja operabilnega raka dojke z negativnimi bezgavkami pri bolnicah z velikim tveganjem recidiva po St.- Gallenskih merilih 1998 (velikost tumorja > 2 cm in/ali negativni ER in PR in/ali visoka histološka/jedrna stopnja (2. do 3. stopnja) in/ali starost < 35 let).
106b [86, 128]
106b [86,
107.0±0.5 FFU***
107,0±0,5 FFE
108 (100 million) PFU/mL
108 (100 milijonov) PFU/ml
108 (100 million) PFU/mL - For all subsequent doses.
108 (100 milijonov) PFU/ml – za vse nadaljnje odmerke.
109 (43.8%)b
0,28
109 x 106 cells/l
109 x 106 celic/l
1093 patients received at least 1 year, and 415 patients have received at least 2 years of treatment with Plegridy.
1.093 bolnikov je zdravilo prejemalo vsaj 1 leto in 415 bolnikov se je z zdravilom Plegridy zdravilo vsaj 2 leti.
10x 1 ml (1 dose) 50x 1 ml (1 dose) 1x 10 ml (10 doses)
10x 1 ml (1 odmerek) 50x 1 ml (1 odmerek) 1x 10 ml (10 odmerkov)
10x 10,000 doses
10x 10.000 odmerkov
10x 2,500 doses
10x 2.500 0dmerkov
10x 5,000 doses
10x 5.000 odmerkov
10x1 capsule (unit dose) +
10x1 kapsul (enkratni
10x1 capsule (unit dose) +
10x1 kapsula (enkratni
10x1 film-coated tablets.
10 x 1 filmsko obloženih tableta
10x1 film-coated tablets.
10 x1 filmsko obloženih tableta
10x1 tablet in all aluminium perforated unit-dose blisters.
10 x 1 tableto v enoodmernih perforiranih pretisnih omotih v celoti iz aluminija.
10x1 tablets
10x1 tablet
10–12 mg/kg bodyweight/day
prašičje enzootske pljučnice
11 - Any excessive air rises to the top of the solution.
11 - Ves odvečni zrak je na površini raztopine.
11 - With the syringe assembly still attached, swirl the vial around gently to completely dissolve the dry Betaferon powder.
11 - Medtem, ko je sklop brizge še vedno pritrjen, vialo nežno zavrtite, da se suh prašek zdravila Betaferon povsem raztopi.
11 Adverse event identified from spontaneous post-marketing reporting with frequency determined utilising the Olanzapine Integrated Database.
11Neželeni učinki, ugotovljeni pri spontanem poročanju v obdobju trženja s pogostostjo, določeno z uporabo integrirane baze podatkov za olanzapin.
11 Adverse event identified from spontaneous post-marketing reporting with frequency determined utilising the Olanzapine Integrated Database.
Neželeni učinki, ugotovljeni pri spontanem poročanju v obdobju trženja s pogostostjo, določeno z uporabo integrirane baze podatkov za olanzapin.
11 capsules (825 mg)
11 kapsul
11 clicks
klikov
11 Diagram M
11 Slika M
11 Hypersensitivity reactions of the skin may occuras itching, rash and urticaria.
11 Pojavijo se lahko preobčutljivostne reakcije kože, npr. srbenje, izpuščaj ali urtikarija.
11 IU
11 i.e.
11 MARKETING AUTHORISATION NUMBER
11 ŠTEVILKA(E) DOVOLJENJ(A) ZA PROMET
11 MARKETING AUTHORISATION NUMBERS
11 ŠTEVILKA(E) DOVOLJENJ(A) ZA PROMET
11 ml/20 ml vial
11 ml/20 ml viala
11 months
11 mesecev
11 OJ No.
11 OJ št.
11 patients were enrolled and 9 patients are on-going in the study.
Vključenih je bilo 11 bolnikov in 9 bolnikov v študiji še sodeluje.
11 SPECIAL STORAGE PRECAUTIONS
POSEBNA NAVODILA ZA SHRANJEVANJE
11 to 24 M
11 do 24 m
11 to less than 14†
11 do manj kot 14
11 to less than 25 kg
11 do manj kot 25 kg
11-13 Moores Rd, Glenorie, NSW, 2157 Australia
11-13 Moores Rd, Glenorie, NSW, 2157 Avstralija
11-15 Clădirea S-Park, Corp B3-B4, Etaj 3 013714 Bucureşti, ROMANIA
11-15 Clădirea S-Park, Corp B3-B4, Etaj 013714 Bucureşti, ROMANIA
11.
ŠKATLA
11.1
+ metformin2
11.2 g/dl.
11,2 g/dl.
11.2 m vs 12.7 m
11,2 m v prim. z
11.3 mg/tablet
11,3 mg/tableto
11.3 ml/h/kg, respectively.
11,3 ml/h/kg.
11.6% of the patients had marginal zone lymphoma (MZL) and 7.1% had small lymphocytic lymphoma (SLL).
11,6 % bolnikov je imelo limfom marginalne cone (marginal zone lymphoma – MZL) in 7,1 % jih je imelo limfom malih limfocitov (small lymphocytic lymphoma – SLL).
11.7 (10.2-17.4)
n=106 11,7 (10,2-17,4)
11.7 (9.66 to 13.27)
11,7 (9,66 do 13,27)
11.84 (-3.4, 27.0)e
a izračunano kot anidulafungin minus flukonazol
11.NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
11.Use aseptic technique to transfer the reconstituted solutions from the vials into the administration container (e.g. empty intravenous bag or glass bottle; not supplied) via a commercially available intravenous tubing transfer set (not supplied).
11.Z aseptično tehniko prenesite rekonstituirano raztopino iz vial v vsebnik za apliciranje (npr. v prazno intravensko vrečo ali steklenico; ni priloženo) z intravenskim cevnim setom za prenos, ki ga kupite (ni priložen).
110 days
110 dni
110 mg/kg at Weeks 0, 2 and 4 followed by subcutaneous doses of 75 mg or 150 mg
110 mg/kg v tednih 0, 2 in 4, nato subkutano odmerjanje 75 mg ali 150 mg
1100 mg prednisone/prednisolone or 20 mg dexamethasone or 80 mg methylprednisolone.
1100 mg prednizona/prednizolona ali 20 mg deksametazona ali 80 mg metilprednizolona.
1107 Budapest HUNGARY
1107 Budapest MADŽARSKA
1107 Budapest HUNGARY
1107 Budapest, Madžarska
1119
Študija
112 (2 x 56) capsules (multipack)
112 (2 x 56) kapsul
112 (2 x 56) capsules (multipack)
112 (2 x 56) kapsul (multipakiranje)
112 (32.3)a,b
112 (32,3 a,b
112 (4 packs of 28) hard capsules.
112 (4 pakiranja po 28) trdih kapsul.
112 (4 wallets of 28) hard capsules.
112 (4 zloženke po 28) trdih kapsul.
112 (4x28) capsules (multipack)
112 kapsul (4 × 28) kapsul (veliko pakiranje)
112 capsules (4 blister cards of 21 x 20 mg and 7 x 80 mg) (140 mg/day dose) Each 28 day pack contains enough medicine for 28 days.
112 kapsul (4 pretisne zgibanke z: 21 x 20 mg in 7 x 80 mg) (odmerek 140 mg/dan) Vsako 28-dnevno pakiranje vsebuje dovolj zdravila za 28 dni.
112 capsules (4 blister cards of 21 x 20mg and 7 x 80 mg) (140 mg/day dose for a 28 day supply)
112 kapsul (4 pretisne zgibanke z: 21 x 20 mg in 7 x 80 mg) (odmerek 140 mg/dan odmerek, zaloga za 28 dni)
112 film-coated tablets
112 filmsko obloženih tablet.
112 film-coated tablets (4 packs of 28 tablets).
112 filmsko obloženih tablet (4 pakiranja po 28 tablet).
112 film-coated tablets.
112 filmsko obloženih tablet.
112 or 196 tablets.
196 tablet.
112 prolonged-release tablets
112 tablet s podaljšanim sproščanjem
112 soft capsules
112 mehkih kapsul
112 tablets
112 tablete
112 tablets (2 x 56)
112 tablet (2 x 56)
112 tablets.
112 tablet
112 x 1 orodispersible tablet
112 x 1 orodisperzibilna tableta
112 x 1 orodispersible tablet:EU/1/09/525/031
112 x 1 orodisperzibilna tableta: EU/1/09/525/031
112 x 1 orodispersible tablet:EU/1/09/525/036
112 x 1 orodisperzibilna tableta: EU/1/09/525/036
112 x 1 orodispersible tablet:EU/1/09/525/041
112 x 1 orodisperzibilna tableta: EU/1/09/525/041
112 x 1 orodispersible tablet:EU/1/09/525/046
112 x 1 orodisperzibilna tableta: EU/1/09/525/046
112 x 1 tablet (unit dose)
112 x 1 tableta (za enkratni odmerek)
1121 Viena
1121 Beč
1121 Vienna Austria
1121 Vienna Avstrija
113.2 micrograms/mL (Cmax) at 0.5 hour postdose (end of infusion), 12.8 micrograms/mL at 6 hour postdose, and 3.0 micrograms/mL at 12 hour postdose.
113,2 mikrogramov/ml (Cmax) 0,5 ure po odmerku (ob koncu infuzije), 12,8 mikrogramov/ml 6 ur po odmerku in 3,0 mikrograme/ml 12 ur po odmerku.
113/207 of patients originally treated with 40 mg Humira every other week were evaluated radiographically at 5 years.
207 bolnikov, ki so bili zdravljeni s 40 mg Trudexe vsak drugi teden, so rentgenografsko ocenili po 5-ih letih.
114 healthy male volunteers received a single 600 mg fixed dose (n=58 administration system, n= 56, syringe).
114 zdravih moških preskušancev je prejelo en fiksni odmerek 600 mg (n = 58: aplikacijski sistem, n = 56: injekcijska brizga).
114.6 (100.1 to 142.9)
114,6 (100,1-142,9)
1143
ROG 1,04
116
N = 346
116 (55.5%)a
0,75 mg/kga
116 (55.5%)a
277 (68%)a
116 patients were enrolled and received initially febuxostat 80 mg QD.
Vključenih je bilo 116 bolnikov, ki so prejemalo prvotni odmerek febuksostat 80 mg enkrat na dan.
116mL p=0.06 (-5, 236)
(-5, 236)
117 50 43 35 33 29 27 11 3 0
117 50 43 35 33 29 27 11 3 0 ipilimumab
117 Allee des Parcs 69800 Saint-Priest France
117 Allee des Parcs 69 800 Saint Priest Francija
117 allee des Parcs, 69 800 Saint Priest, France
117 allee des Parcs, 69800 Saint Priest, Francija
117, Allée des Parcs, 69800 Saint-Priest, France
117, Allée des Parcs, 69800 Saint-Priest, Francija
117-275 ng/mL (25th-75th percentile range).
Geometrična sredina najmanjše koncentracije dabigatrana, merjena zjutraj na koncu odmernega intervala (t.j.
119 cells/mm3
329 (293, 364)
1199 patients were randomised 2:1 to receive either enzalutamide orally at a dose of 160 mg once daily (N = 800) or placebo once daily (N = 399).
1199 bolnikov so v razmerju 2:1 randomizirali na prejemanje enzalutamida peroralno v odmerku 160 mg enkrat na dan (n = 800) ali na prejemanje placeba enkrat na dan (n = 399).
11q deletion
Delecija 11q
12 (3 x 4) pre- filled pens (multipack)
12 (3 x 4) napolnjenih injekcijskih peresnikov (večodmerno pakiranje)
12 (3 x 4) pre- filled syringes (multipack)
12 (3 x 4) napolnjenih injekcijskih brizg (skupno pakiranje)
12 (3 x 4) pre- filled syringes (multipack)
12 (3 x 4) napolnjenih injekcijskih brizg (večodmerno pakiranje)
12 (3 x 4) pre-filled pens (multipack)
12 (3 x 4) napolnjenih injekcijskih peresnikov (skupno pakiranje)